Achillion Pharmaceuticals, Inc. (ACHN) reported fourth quarter EPS of ($0.21) before the opening bell Thursday, compared to the consensus estimate of ($0.18). Net loss for the three months ended December 31, 2014 came in at $21.6 million, compared to a net loss of $13.4 million in 4Q/13. The stock is currently down nearly 9% to $10.59.
For the full-year 2014, the company’s net loss was $69.0 million, or $0.70 per share, compared to a net loss of $58.9 million for full year 2013, or $0.63 per share.
For FY15, ACHN provided EPS guidance of ($0.95) versus consensus of ($0.85) per share.
On valuation measures, Achillion Pharmaceuticals Inc. shares, trade with a P/E to growth ratio of (1.00). The median Wall Street price target on the name is $20.50 with a high target of $25.00. Currently ticker boasts 9 ‘Buy’ endorsements, compared to 1 ’Holds’ and no ‘Sell’.
In terms of effectiveness, ACHN has a t-12 return on assets and equity of (24.97%) and (42.79%), respectively. The $1.17 billion market cap company reported $159.16 million in cash vs. $279K in long-term liabilities in its most recent quarter.
ACHN currently prints a one year return of about 217.76% and a year-to-date loss of 5.06%.
Achillion Pharmaceuticals Inc. is a biopharmaceutical company that develops, and commercializes anti-infective drug therapies in the United States and internationally. The company was founded in 1998 and is headquartered in New Haven, Connecticut.